Skip to content

US · ARCT · BIOTECHNOLOGY

Arcturus Therapeutics Holdings Inc. (ARCT) intrinsic value and stock valuation

$7.45as of 2026-11-21 · Mkt cap 177.93M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Arcturus Therapeutics Holdings Inc. DCF and intrinsic value

InvestorsCraft values ARCT with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from ARCT’s statements →

Arcturus Therapeutics Holdings Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology San Diego, CA 92121 arcturusrx.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$67.2M+47.8% 5y CAGRd
20112025
Net income
-$-65.78M
20112025
Free cash flow
-$-74.27M
20112025
Total equity
$214M-11.6% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$67.2M$138.4M$157.8M$205.8M$12.4M
Operating income-$-74.95M-$-95.67M-$-78.2M$12.2M-$-202.85M
Net income-$-65.78M-$-80.94M-$-29.73M$9.35M-$-203.67M
EPSd-$-2.4M-$-3M-$-1.12M$345.1K-$-7.74M
Operating cash flow-$-74.27M-$-59.75M-$-18.1M$32M-$-135.04M
Capital expenditure-$-230K-$-650K-$-2.9M-$-7.73M-$-3.41M
Free cash flow-$-74.27M-$-60.4M-$-21M$24.3M-$-138.45M
Total assets$271.2M$344.1M$429.4M$450.4M$392.8M
Total debt$25M$28.6M$30.2M$94.8M$69.2M
Net debt-$-205.91M-$-208.48M-$-261.79M-$-297.13M-$-301.35M
Total equity$214M$241M$278.5M$270.3M$228.2M
Cash and short-term investments$230.9M$237M$292M$391.9M$370.5M
Income statement
20252024202320222021
Revenue$67.2M$138.4M$157.8M$205.8M$12.4M
Cost of revenue$3.02M$0.00$0.00$0.00$0.00
Gross profit$64.2M$138.4M$157.8M$205.8M$12.4M
Research and development expenses$112.2M$195.2M$192.1M$147.8M$173.8M
Selling, general and administrative expenses$46.1M$52.8M$52.9M$46.1M$41.5M
Other expenses-$-19.14M-$-13.92M-$-9.05M-$-240K$0.00
Operating expenses$139.2M$234.1M$236M$193.6M$215.2M
Cost and expenses$142.2M$234.1M$236M$193.6M$215.2M
Interest income$10.1M$15.2M$17.4M$2.58M$750K
Interest expense$0.00$0.00$770K$3M$2.67M
Depreciation and amortization$3.02M$3.54M$2.96M$1.53M$1.19M
Ebitda-$-62.76M-$-77.4M-$-24.16M$15.2M-$-199.81M
Operating income-$-74.95M-$-95.67M-$-78.2M$12.2M-$-202.85M
Total other income/expenses, net$9.17M$14.7M$50.3M-$-1.53M-$-820K
Income before tax-$-65.78M-$-80.94M-$-27.89M$10.6M-$-203.67M
Income tax expense$0.00-$0.00$1.83M$1.29M$0.00
Net income-$-65.78M-$-80.94M-$-29.73M$9.35M-$-203.67M
Weighted average shares outstanding$27.4M$27M$26.6M$26.5M$26.3M
Weighted average diluted shares outstanding$27.4M$27M$26.6M$27.1M$26.3M
Balance sheet
20252024202320222021
Cash and short-term investments$230.9M$237M$292M$391.9M$370.5M
Net receivables$5.56M$3.97M$32.1M$2.76M$3.37M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$241.5M$306M$386.6M$403.3M$379M
Property, plant and equipment, net$27.8M$36.2M$40.9M$45M$11.3M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$1.89M$0.00$1.89M$0.00$520K
Total non-current assets$29.7M$38.1M$42.8M$47.1M$13.9M
Total assets$271.2M$344.1M$429.4M$450.4M$392.8M
Accounts payable$4.24M$7.19M$5.28M$7.45M$10.1M
Short-term debt$4.21M$3.55M$4.31M$64.5M$24M
Deferred revenue$8.25M$21.9M$47.3M$36.1M$43.5M
Total current liabilities$36.4M$65.5M$82M$127M$99.5M
Long-term debt$20.8M$25M$25.9M$30.2M$45.1M
Deferred revenue, non-current$0.00$12.6M$42.5M$20.1M$0.00
Total non-current liabilities$20.8M$37.6M$68.9M$53.1M$65.1M
Capital lease obligations$25M$28.6M$30.2M$34.1M$6.04M
Total liabilities$57.2M$103.1M$150.9M$180.1M$164.6M
Common stock$30K$30K$30K$30K$30K
Retained earnings-$-514.59M-$-448.81M-$-367.87M-$-338.14M-$-347.49M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$214M$241M$278.5M$270.3M$228.2M
Total investments$1.89M$0.00$1.89M$0.00$520K
Total debt$25M$28.6M$30.2M$94.8M$69.2M
Net debt-$-205.91M-$-208.48M-$-261.79M-$-297.13M-$-301.35M
Cash flow statement
20252024202320222021
Net income-$-65.78M-$-80.94M-$-29.73M$9.35M-$-203.67M
Depreciation and amortization$3.02M$3.54M$2.96M$1.53M$1.19M
Stock-based compensation$25.4M$38M$34.7M$30.6M$28.9M
Change in working capital-$-39.2M-$-20.81M$7.38M-$-12.56M$32.6M
Accounts receivable-$-1.59M$28.1M-$-29.3M$600K-$-1.24M
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-2.96M$1.92M-$-2.24M-$-3.11M-$-770K
Net cash provided by operating activities-$-74.27M-$-59.75M-$-18.1M$32M-$-135.04M
Investments in property, plant and equipment-$-230K-$-650K-$-2.9M-$-7.73M-$-3.41M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-230K-$-650K-$-2.9M-$-7.73M-$-3.41M
Common stock issued$13.4M$680K$610K$410K$520K
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$13.4M$5.42M-$-24.09M-$-2.86M$48M
Net change in cash-$-61.12M-$-54.98M-$-45.09M$21.4M-$-90.43M
Cash at end of period$232.8M$293.9M$348.9M$394M$372.6M
Operating cash flow-$-74.27M-$-59.75M-$-18.1M$32M-$-135.04M
Capital expenditure-$-230K-$-650K-$-2.9M-$-7.73M-$-3.41M
Free cash flow-$-74.27M-$-60.4M-$-21M$24.3M-$-138.45M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Arcturus Therapeutics Holdings Inc.

        Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on RNA-based medicines, developing a pipeline of vaccines for infectious diseases alongside treatments for rare liver and respiratory conditions across the United States. Its notable development programs encompass LUNAR-OTC, designed for ornithine transcarbamylase (OTC) deficiency, and LUNAR-CF, targeting cystic fibrosis lung disease caused by specific CFTR gene mutations. The company also advances vaccine initiatives such as LUNAR-COV19 and LUNAR-FLU. Arcturus has cultivated a range of strategic collaborations, including partnerships with Vinbiocare Biotechnology Joint Stock Company for manufacturing COVID-19 vaccines; Janssen Pharmaceuticals, Inc., to create nucleic acid-based therapies for hepatitis B virus; Ultragenyx Pharmaceutical, Inc., for developing mRNA therapeutics aimed at rare disease targets; CureVac AG, to progress mRNA therapeutic and vaccine candidates across various indications; the Singapore Economic Development Board and Duke-NUS Medical School, specifically for the LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc., focused on discovering siRNA medicines for non-alcoholic steatohepatitis (NASH). Founded in 2013, Arcturus Therapeutics maintains its corporate headquarters in San Diego, California.

        CEO
        Joseph E. Payne
        Employees
        111
        Beta
        2.36

        Explore

        Frequently asked questions

        What is the intrinsic value of Arcturus Therapeutics Holdings Inc. (ARCT)?

        Arcturus Therapeutics Holdings Inc. (ARCT) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is ARCT undervalued?

        ARCT trades at a price of $7.45 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.